In the liver, a selective p38 mitogen‐activated protein kinase (MAPK) inhibitor is shown to ameliorate liver fibrosis through the downregulation of Runx2 in a rat model,17 and Runx2 promotes epithelial–mesenchymal transition and vasculogenic mimicry in hepatocellular carcinoma,18 which indicates that Runx2 serves as a fibrogenic or tumorigenic factor in the liver. Here, RUNX2 is linked to Hepatic fibrosis.